Cheshire-based Crawford Healthcare announces further acquisition in advanced wound care

A Cheshire skincare company has announced the acquisition of Archimed LLP and its two advanced wound care brands Iodozyme and Oxyzyme.

The brands fit perfectly with Crawford Healthcare’s existing Flaminal brand which is showing strong growth in the advanced wound care market.

Along with the acquisition of the Exsalt technology this acquisition gives Crawford a broad approach for treating a wide spectrum of wound infection.

Both brands are at the cutting edge of wound healing using patented technology to kill infection in wounds and aid wound healing. Both are Class 3 medical devices with strong claims on their mode of action and have great international potential.

Crawford, of Knutsford, continues to grow at over 30% per annum in the UK, significantly faster than the Advanced Wound Care market, and its international expansion continues - by the end of 2013 its products will be sold on every continent. This is the 12th acquisition / licence deal the group has completed since 2011 and the transaction is value and growth enhancing for Crawford.

Commenting on the acquisition Richard Anderson, CEO of Crawford Healthcare, said: “This acquisition further strengthens our portfolio and technology base. With Crawford’s Sales and Marketing strength we are confident we can drive further revenues in the anti-microbial sector. It also makes the Crawford portfolio more attractive to our international partners.”

Chris Hunt, CEO of Archimed LLP added: “We are delighted to have reached agreement with Crawford Healthcare. Having established themselves in the market, Oxyzyme and Iodozyme will now benefit greatly from the considerable sales and marketing strength that Crawford will provide.”